Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
25.54
+0.14 (0.55%)
Dec 27, 2024, 4:00 PM EST - Market closed
Royalty Pharma Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Royalty Pharma stock have an average target of 41.67, with a low estimate of 28 and a high estimate of 51. The average target predicts an increase of 63.16% from the current stock price of 25.54.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 25, 2024.
Analyst Ratings
The average analyst rating for Royalty Pharma stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $60 → $40 | Strong Buy | Maintains | $60 → $40 | +56.62% | Oct 25, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $50 → $51 | Strong Buy | Maintains | $50 → $51 | +99.69% | Aug 14, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $48 → $51 | Buy | Maintains | $48 → $51 | +99.69% | Jul 11, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $28 | Strong Buy → Hold | Downgrades | $28 | +9.63% | Jun 3, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $40 → $38 | Strong Buy | Maintains | $40 → $38 | +48.79% | Apr 12, 2024 |
Financial Forecast
Revenue This Year
2.64B
from 2.35B
Increased by 12.21%
Revenue Next Year
2.94B
from 2.64B
Increased by 11.13%
EPS This Year
4.03
from 2.53
Increased by 59.24%
EPS Next Year
4.46
from 4.03
Increased by 10.62%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.9B | 3.6B | 3.9B | |||
| Avg | 2.6B | 2.9B | 3.2B | |||
| Low | 2.0B | 2.3B | 2.6B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 24.5% | 37.1% | 33.1% | |||
| Avg | 12.2% | 11.1% | 10.6% | |||
| Low | -13.4% | -11.6% | -12.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 4.34 | 5.45 | 5.91 | |||
| Avg | 4.03 | 4.46 | 4.92 | |||
| Low | 3.31 | 3.72 | 4.02 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 71.2% | 35.1% | 32.4% | |||
| Avg | 59.2% | 10.6% | 10.2% | |||
| Low | 30.5% | -7.7% | -10.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.